MIRM Mirum Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MIRM

Price (delayed)

$25.84

Market cap

$1.21B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4

Enterprise value

$1.24B

Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Mirum's lead product candidate, maralixibat, ...

Highlights
The revenue has soared by 142% YoY and by 29% from the previous quarter
The company's gross profit has surged by 115% YoY and by 18% QoQ
Mirum Pharmaceuticals's equity has soared by 75% YoY but it has decreased by 8% from the previous quarter
The company's debt has surged by 116% YoY
The net income has contracted by 20% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://mirumpharma.com
Peers: OMER OMGA

Key stats

What are the main financial stats of MIRM
Market
Shares outstanding
47M
Market cap
$1.21B
Enterprise value
$1.24B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.84
Price to sales (P/S)
5.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.63
Earnings
Revenue
$186.37M
EBIT
-$147.32M
EBITDA
-$135.87M
Free cash flow
-$71.05M
Per share
EPS
-$4
Free cash flow per share
-$1.74
Book value per share
$5.33
Revenue per share
$4.56
TBVPS
$9.63
Balance sheet
Total assets
$646.62M
Total liabilities
$397.95M
Debt
$308.14M
Equity
$248.67M
Working capital
$300.48M
Liquidity
Debt to equity
1.24
Current ratio
4.45
Quick ratio
4.07
Net debt/EBITDA
-0.16
Margins
EBITDA margin
-72.9%
Gross margin
74.8%
Net margin
-87.7%
Operating margin
-58.6%
Efficiency
Return on assets
-31.5%
Return on equity
-88.6%
Return on invested capital
-48.6%
Return on capital employed
-26.3%
Return on sales
-79%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MIRM stock price

How has the Mirum Pharmaceuticals stock price performed over time
Intraday
0.94%
1 week
5.64%
1 month
4.45%
1 year
-9.62%
YTD
-12.47%
QTD
2.87%

Financial performance

How have Mirum Pharmaceuticals's revenue and profit performed over time
Revenue
$186.37M
Gross profit
$139.34M
Operating income
-$109.15M
Net income
-$163.42M
Gross margin
74.8%
Net margin
-87.7%
The revenue has soared by 142% YoY and by 29% from the previous quarter
The company's gross profit has surged by 115% YoY and by 18% QoQ
The operating margin has soared by 66% YoY and by 23% from the previous quarter
The company's net margin has surged by 50% YoY and by 23% QoQ

Growth

What is Mirum Pharmaceuticals's growth rate over time

Valuation

What is Mirum Pharmaceuticals stock price valuation
P/E
N/A
P/B
4.84
P/S
5.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.63
The EPS has grown by 7% from the previous quarter
Mirum Pharmaceuticals's equity has soared by 75% YoY but it has decreased by 8% from the previous quarter
MIRM's price to book (P/B) is 34% lower than its last 4 quarters average of 7.3 and 7% lower than its 5-year quarterly average of 5.2
The revenue has soared by 142% YoY and by 29% from the previous quarter
MIRM's price to sales (P/S) is 33% lower than its last 4 quarters average of 8.4

Efficiency

How efficient is Mirum Pharmaceuticals business performance
The ROS has soared by 52% YoY and by 22% from the previous quarter
Mirum Pharmaceuticals's return on assets has increased by 25% YoY and by 15% QoQ
The ROE has increased by 15% QoQ and by 13% YoY
The ROIC has grown by 11% YoY and by 7% from the previous quarter

Dividends

What is MIRM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MIRM.

Financial health

How did Mirum Pharmaceuticals financials performed over time
MIRM's total assets is 62% higher than its total liabilities
The total liabilities has soared by 89% YoY and by 4.3% from the previous quarter
MIRM's total assets has soared by 83% YoY
The company's debt is 24% higher than its equity
The company's debt has surged by 116% YoY
Mirum Pharmaceuticals's equity has soared by 75% YoY but it has decreased by 8% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.